About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

AI infrastructure company SiliconFlow announced on the 20th it completed a B+ round Phase II and a C round, bringing year-to-date equity financing to nearly CNY 2.9 billion. New investors included China Internet Investment Fund, Guoxin Fund, China Mo

2026-09-20

AI infrastructure company SiliconFlow announced on the 20th it completed a B+ round Phase II and a C round, bringing year-to-date equity financing to nearly CNY 2.9 billion. New investors included China Internet Investment Fund, Guoxin Fund, China Mobile Chain Leader Fund and China Orient Asset International; existing backers Yaotu Capital, Shengyi Capital and Guotai Venture Capital Group made follow-on investments. Proceeds will fund R&D on inference engines, heterogeneous compute scheduling and model–chip adaptation, expand a token supply platform and accelerate global market rollout to boost token production efficiency and scalable services across multi-model, multi-chip environments.

Other News
2026-09-20

Sept. 20 — National Medical Products Administration deputy director Yang Sheng said at a State Council Information Office briefing that during the 15th Five‑Year Plan period the NMPA will issue opinions to strengthen the drug safety responsibility fr

Sept. 20 — National Medical Products Administration deputy director Yang Sheng said at a State Council Information Office briefing that during the 15th Five‑Year Plan period the NMPA will issue opinions to strengthen the drug safety responsibility framework, advance revisions to the Medical Device Administration Law and the Regulations on Protection of Traditional Chinese Medicine Varieties, and fully implement the Drug Administration Law implementing rules and supporting systems. The agency will roll out a drug and medical‑device standards upgrade plan, compile a 2030 edition of the Chinese Pharmacopoeia prioritizing essential medicines, drugs covered by medical insurance and high-risk formulations, and step up standards research in frontier areas such as brain‑computer interfaces to drive quality improvements.
2026-09-20

On the 19th, Slovak Prime Minister Fico said the Russia-Ukraine war is not Slovakia’s war and Slovakia should not be drawn into a direct military confrontation between NATO and Russia. He said parties seeking to provoke a NATO-Russia military clash s

On the 19th, Slovak Prime Minister Fico said the Russia-Ukraine war is not Slovakia’s war and Slovakia should not be drawn into a direct military confrontation between NATO and Russia. He said parties seeking to provoke a NATO-Russia military clash should assume responsibility rather than shifting risk onto other NATO members. Fico called for immediate peace talks, warned further military escalation would raise European security and economic risks, and urged a more rational approach to NATO’s Article 5 collective-defense clause.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.